Evidence map›Paper›PMID 27811146›Full record

ArticleAnnals of the rheumatic diseases2017

PP2A plays a key role in inflammation and cancer through tristetraprolin activation.

Ion Cristóbal, Blanca Torrejón, Juan Madoz-Gúrpide, Federico Rojo, Jesús García-Foncillas

Open access · bronzeAbstract readLetterComment
PubMed Publisher
In one paragraph

Article in Annals of the rheumatic diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.8field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Roles of Tristetraprolin in Tumorigenesis.International journal of molecular sciences · 2018
    Review
  6. Article
  7. The role of RNA-binding protein tristetraprolin in cancer and immunity.Medical oncology (Northwood, London, England) · 2017
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Ion CristóbalTranslational Oncology Division, Oncohealth Institute, IIS-Fundacion Jimenez Diaz, UAM, University Hospital 'Fundacion Jimenez Diaz', Madrid, Spain.
Blanca TorrejónTranslational Oncology Division, Oncohealth Institute, IIS-Fundacion Jimenez Diaz, UAM, University Hospital 'Fundacion Jimenez Diaz', Madrid, Spain.
Juan Madoz-GúrpidePathology Department, University Hospital 'Fundacion Jimenez Diaz', Autonomous University of Madrid, Madrid, Spain.
Federico RojoPathology Department, University Hospital 'Fundacion Jimenez Diaz', Autonomous University of Madrid, Madrid, Spain.
Jesús García-FoncillasTranslational Oncology Division, Oncohealth Institute, IIS-Fundacion Jimenez Diaz, UAM, University Hospital 'Fundacion Jimenez Diaz', Madrid, Spain.
Hospital Universitario Fundación Jiménez Díaz · ESUniversidad Autónoma de Madrid · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

ArthritisNeoplasmsGene ExpressionHumansInflammationTristetraprolinTristetraprolinArthritisChemokinesInflammation

Identifiers

PMID27811146
OpenAlexW2547239247

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.